Skip to main content

Association for Molecular Pathology 2022 (AMP)

We will be at the Association for Molecular Pathology (AMP) 2022 Annual Meeting & Expo, which will take place November 1-5 in Phoenix, Arizona. At the conference, our team can tell you more about the benefits of non-invasive sample types such as urine in oncology and infectious disease testing and research.

We look forward to seeing you in November!

Disclaimer

Novosanis is a wholly owned subsidiary of OraSure Technologies, Inc. (NASDAQ: OSUR), and an innovative developer and producer of medical devices improving the quality of diagnostic tests for infectious diseases and oncology. The Colli-Pee® family, the heart of the company, allows volumetric and standardized collection of first-void urine. The platform consists of variants capturing a range of urine volumes for different application purposes. Urine collection through the Colli-Pee® device is easy, comfortable, and more accurate than a regular urine cup. First-void urine has shown to improve detection of infectious diseases, including sexually transmitted infections as well as for some cancers applications. The Colli-Pee® device enables immediate mixing of the first-void urine sample with a preservative, improving stability of the urine specimen. Novosanis markets its products worldwide and has a global customer base.